AZD-9291 (BioDeep_00001871434)
代谢物信息卡片
Osimertinib
化学式: C28H33N7O2 (499.2695598)
中文名称: 奥希替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChI: InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:90943
- PubChem: 71496458
- DrugBank: DB09330
- ChEMBL: CHEMBL3353410
- CAS: 1421373-65-0
分类词条
相关代谢途径
Reactome(4)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Lin Cao, Zhiyan Qin, Ting Yu, Xupeng Bai, Shiqin Jiang, Daifei Wang, Fangqing Ning, Min Huang, Jing Jin. Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer.
Biochemical pharmacology.
2024 Jun; 224(?):116207. doi:
10.1016/j.bcp.2024.116207. [PMID: 38621425] - Jing Zhao, Dongming Yan, Yue Li, Xiaoqing Xu, Fengling Li, Shuang Zhang, Jingyi Jin, Furong Qiu. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2024 Apr; 1237(?):124100. doi:
10.1016/j.jchromb.2024.124100. [PMID: 38547701] - Chang Lu, Xue-Wu Wei, Zhen Wang, Zhen Zhou, Yu-Tao Liu, Di Zheng, Yong He, Zhan-Hong Xie, Yong Li, Yan Zhang, Yi-Chen Zhang, Zi-Jian Huang, Shi-Qi Mei, Jia-Qi Liu, Xu-Hui Guan, Yu Deng, Zhi-Hong Chen, Hai-Yan Tu, Chong-Rui Xu, Hua-Jun Chen, Wen-Zhao Zhong, Jin-Ji Yang, Xu-Chao Zhang, Tony S K Mok, Yi-Long Wu, Qing Zhou. Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2024 Apr; 19(4):601-612. doi:
10.1016/j.jtho.2023.11.016. [PMID: 37981218] - Tong-Tong Wu, Yu-Yi Chen, Zi-Chun Yuan, Guo-Wang Yang, Gan-Lin Zhang. Synergy of de-walled Ganoderma Lucidum spore powder (GLSP) on targeted therapy in advanced non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutant: protocol for a randomized, double-blind, placebo-controlled study.
BMC complementary medicine and therapies.
2024 Mar; 24(1):125. doi:
10.1186/s12906-024-04416-2. [PMID: 38500118] - Yikuan Shen, Songgao Lou, Jiansong Zhang. Interstitial pneumonia disease induced by osimertinib combined with savolitinib targeted therapy in a lung cancer patient: A case report.
Medicine.
2024 Jan; 103(1):e36208. doi:
10.1097/md.0000000000036208. [PMID: 38181277] - Xiao-Jun Ren, Ming-Hong Lei, Ying-Xia Cheng, Yun Luo. Colonic mucosal diffuse congestion associated with Osimertinib.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2023 Oct; 29(7):1781-1784. doi:
10.1177/10781552231184182. [PMID: 37338466] - Yang Lei, Jia Duan, Qiong Zhang, Qing Li. Comparation of EGFR-TKI (EGFR tyrosine kinase inhibitors) combination therapy and osimertinib for untreated EGFR-mutated advanced non-small cell lung cancers: A systematic review and network meta-analysis.
Medicine.
2023 Jul; 102(30):e34483. doi:
10.1097/md.0000000000034483. [PMID: 37505120] - Xuyi Zhan, Shaoyin Bao, Xumei Li, Shaojun Zhou, Maha Raja Dahar, Nengming Lin, Xiugui Chen, Chengshan Niu, Kaige Ji, Yusheng Wu, Kui Zeng, Zhihua Tang, Lushan Yu. Metabolism and pharmacokinetic study of deuterated osimertinib.
Biopharmaceutics & drug disposition.
2023 Apr; 44(2):165-174. doi:
10.1002/bdd.2347. [PMID: 36649539] - Qian Liang, Miaomiao Gong, Jing-Hua Zou, Ming-Yu Luo, Lu-Lu Jiang, Cheng Wang, Ning-Xiang Shen, Mo-Cong Zhang, Lu Xu, Hui-Min Lei, Ke-Ren Zhang, Rui Zhang, Guanglei Zhuang, Liang Zhu, Hong-Zhuan Chen, Lu Zhou, Ying Shen. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
2023 Mar; 68(?):100957. doi:
10.1016/j.drup.2023.100957. [PMID: 36990047] - Hiroto Konishi, Yuya Haga, Ying Lin, Hirofumi Tsujino, Kazuma Higashisaka, Yasuo Tsutsumi. Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis.
Biochemical and biophysical research communications.
2023 01; 641(?):116-122. doi:
10.1016/j.bbrc.2022.12.029. [PMID: 36527745] - Fang Xu, Xin Zhang, Zhipeng Chen, Sheng He, Jing Guo, Lei Yu, Yongjin Wang, Caiyun Hou, Hawaa Ai-Furas, Zongyao Zheng, Jeff B Smaill, Adam V Patterson, Zhi-Min Zhang, Liang Chen, Xiaomei Ren, Ke Ding. Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.
Journal of medicinal chemistry.
2022 10; 65(20):14032-14048. doi:
10.1021/acs.jmedchem.2c01246. [PMID: 36173763] - Lu Liang, Hua He, Shiyao Jiang, Yueying Liu, Jingjing Huang, Xiaoyan Sun, Yi Li, Yiqun Jiang, Li Cong. TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma.
International journal of molecular sciences.
2022 Sep; 23(18):. doi:
10.3390/ijms231810415. [PMID: 36142328] - Fatemeh Aghai-Trommeschlaeger, Sebastian Zimmermann, Anja Gesierich, Charis Kalogirou, Maria-Elisabeth Goebeler, Pius Jung, Theo Pelzer, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Clinical biochemistry.
2022 Jul; 105-106(?):35-43. doi:
10.1016/j.clinbiochem.2022.04.011. [PMID: 35483452] - Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Hao Sun, Kai Yin, Ben-Yuan Jiang, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Chong-Rui Xu, Zhen Wang, Hua-Jun Chen, De-Xiang Zhou, Yi-Long Wu. Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.
BMC medicine.
2022 05; 20(1):197. doi:
10.1186/s12916-022-02387-0. [PMID: 35644609] - Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Ouki Kuniyoshi, Itaru Sato, Naoki Nakaya, Hideo Nakajima, Motonori Kimura, Jun Hakamata, Naoya Suehiro, Hideo Nakada, Shinnosuke Ikemura, Aya Jibiki, Hitoshi Kawazoe, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 May; 1199(?):123245. doi:
10.1016/j.jchromb.2022.123245. [PMID: 35436724] - Ying Jin, Chen Lin, Xun Shi, Qiong He, Junrong Yan, Xinmin Yu, Ming Chen. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.
BMC cancer.
2022 May; 22(1):586. doi:
10.1186/s12885-022-09683-1. [PMID: 35643428] - Hao Chen, Mengzhen Lai, Tao Zhang, Yuqing Chen, Linjiang Tong, Sujie Zhu, Yang Zhou, Xiaomei Ren, Jian Ding, Hua Xie, Xiaoyun Lu, Ke Ding. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.
Journal of medicinal chemistry.
2022 05; 65(9):6840-6858. doi:
10.1021/acs.jmedchem.2c00168. [PMID: 35446588] - G P Vadla, B Daghat, N Patterson, V Ahmad, G Perez, A Garcia, Y Manjunath, J T Kaifi, G Li, C Y Chabu. Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction.
Scientific reports.
2022 04; 12(1):6693. doi:
10.1038/s41598-022-10598-x. [PMID: 35461372] - Celine Noha Haeller, Lilly Khamsy, Jonas Kloepper, Luis Schiappacasse, Hasna Bouchaab, Solange Peters, Ann Schalenbourg. Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib.
Klinische Monatsblatter fur Augenheilkunde.
2022 04; 239(4):586-589. doi:
10.1055/a-1771-6452. [PMID: 35472811] - Hong-Yi Zhao, Hai-Peng Wang, Yu-Ze Mao, Hao Zhang, Minhang Xin, Xiao-Xiao Xi, Hao Lei, Shuai Mao, Dong-Hui Li, San-Qi Zhang. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
Journal of medicinal chemistry.
2022 03; 65(6):4709-4726. doi:
10.1021/acs.jmedchem.1c01827. [PMID: 35254067] - Hiroshi Sugimoto, Satoshi Matsumoto, Yukio Tsuji, Keisuke Sugimoto. Elevated serum creatine kinase levels due to osimertinib: A case report and review of the literature.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2022 Mar; 28(2):489-494. doi:
10.1177/10781552211042271. [PMID: 34605320] - Li Li, Zhujun Li, Conghua Lu, Jianghua Li, Kejun Zhang, Caiyu Lin, Xiaolin Tang, Zhulin Liu, Yimin Zhang, Rui Han, Yubo Wang, Mingxia Feng, Yuan Zhuang, Chen Hu, Yong He. Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.
Communications biology.
2022 02; 5(1):155. doi:
10.1038/s42003-022-03111-7. [PMID: 35197546] - Xin Xiong, Yuanyuan Zhang, Ziyu Wang, Congya Zhou, Ping Yang, Xin Du, Li Yang, Wei Liu. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Clinica chimica acta; international journal of clinical chemistry.
2022 Feb; 527(?):1-10. doi:
10.1016/j.cca.2021.12.028. [PMID: 34999058] - Shan Li, Tao Zhang, Su-Jie Zhu, Chong Lei, Mengzhen Lai, Lijie Peng, Linjiang Tong, Zilu Pang, Xiaoyun Lu, Jian Ding, Xiaomei Ren, Cai-Hong Yun, Hua Xie, Ke Ding. Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.
ACS medicinal chemistry letters.
2022 Feb; 13(2):196-202. doi:
10.1021/acsmedchemlett.1c00555. [PMID: 35178175] - Jun Liao, Yihua Huang, Jiadi Gan, Lanlan Pang, Wael A S Ali, Yunpeng Yang, Likun Chen, Li Zhang, Wenfeng Fang. Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status.
Cancer control : journal of the Moffitt Cancer Center.
2022 Jan; 29(?):10732748221081360. doi:
10.1177/10732748221081360. [PMID: 35201951] - Yukari Tsubata, Kana Watanabe, Ryota Saito, Atsushi Nakamura, Hiroshige Yoshioka, Mami Morita, Ryoichi Honda, Nobuhiro Kanaji, Satoshi Ohizumi, Daisuke Jingu, Taku Nakagawa, Kensuke Nakazawa, Atsuto Mouri, Susumu Takeuchi, Naoki Furuya, Yuki Akazawa, Kiyotaka Miura, Eiki Ichihara, Makoto Maemondo, Satoshi Morita, Kunihiko Kobayashi, Takeshi Isobe. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
International journal of clinical oncology.
2022 Jan; 27(1):112-120. doi:
10.1007/s10147-021-02043-2. [PMID: 34643820] - Takayuki Niitsu, Terumasa Hayashi, Junji Uchida, Takafumi Yanase, Satoshi Tanaka, Munenori Kuroyama, Kiyonobu Ueno. Drug-Induced Kidney Injury Caused by Osimertinib: Report of a Rare Case.
Nephron.
2022; 146(1):58-63. doi:
10.1159/000518774. [PMID: 34569520] - Zhen Chen, Karin A Vallega, Haiying Chen, Jia Zhou, Suresh S Ramalingam, Shi-Yong Sun. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
Pharmacological research.
2022 01; 175(?):105998. doi:
10.1016/j.phrs.2021.105998. [PMID: 34826601] - Shao-Jun Chen, Yan-Hua Bi, Li-Hua Zhang. Systematic analysis of the potential off-target activities of osimertinib by computational target fishing.
Anti-cancer drugs.
2022 01; 33(1):e434-e443. doi:
10.1097/cad.0000000000001229. [PMID: 34459459] - Yacine Tandjaoui-Lambiotte, Yanis Akrour, Aude Gibelin, Frederic Gonzalez, Annabelle Stoclin, Anne-Sophie Moreau, Paul Jaubert, Anne Oppenheimer, Boris Duchemann, Stéphane Gaudry. Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Chest.
2022 01; 161(1):284-287. doi:
10.1016/j.chest.2021.06.079. [PMID: 34302842] - Hongxue Meng, Lan Huang, Jiahui Wang, Yingxu Zhou, Meng Wang, Zhaoyang Yang, Xuan Hong. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.
International journal of clinical practice.
2021 Dec; 75(12):e14877. doi:
10.1111/ijcp.14877. [PMID: 34525256] - Hiroyuki Yamaguchi, Kazushige Wakuda, Minoru Fukuda, Hirotsugu Kenmotsu, Hiroshi Mukae, Kentaro Ito, Kenji Chibana, Kohji Inoue, Satoru Miura, Kentaro Tanaka, Noriyuki Ebi, Takayuki Suetsugu, Taishi Harada, Keisuke Kirita, Toshihide Yokoyama, Yuki Nakatani, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio. A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2021 12; 16(12):2121-2132. doi:
10.1016/j.jtho.2021.07.026. [PMID: 34419684] - Hiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katuyuki Kiura, Yuta Takashima, Seiji Yano, Junji Koyama, Takahiro Fukushima, Junko Hamamoto, Hideki Terai, Shinnosuke Ikemura, Ryo Takemura, Koichi Goto, Kenzo Soejima. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands).
2021 12; 162(?):140-146. doi:
10.1016/j.lungcan.2021.10.006. [PMID: 34808485] - Yuji Mukai, Azusa Wakamoto, Tae Hatsuyama, Tatsunari Yoshida, Hideki Sato, Akihisa Fujita, Nobuo Inotsume, Takaki Toda. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Therapeutic drug monitoring.
2021 12; 43(6):772-779. doi:
10.1097/ftd.0000000000000895. [PMID: 33871406] - Julie C L Fournier, John P Evans, Francesca Zappacosta, Daniel A Thomas, Vipulkumar K Patel, Gemma V White, Sebastien Campos, Nicholas C O Tomkinson. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ.
ACS chemical biology.
2021 09; 16(9):1644-1653. doi:
10.1021/acschembio.1c00225. [PMID: 34397208] - Qian Zeng, Han Gao, Longdan Zhang, Shouming Qin, Yongyao Gu, Quanfang Chen. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Anti-cancer drugs.
2021 09; 32(8):890-893. doi:
10.1097/cad.0000000000001094. [PMID: 34232939] - Yumi Harada, Hitomi Sekine, Kunitsugu Kubota, Daichi Sadatomi, Seiichi Iizuka, Naoki Fujitsuka. Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2021 Sep; 141(?):111860. doi:
10.1016/j.biopha.2021.111860. [PMID: 34246954] - Tse-Hung Huang, Ntlotlang Mokgautsi, Yan-Jiun Huang, Alexander T H Wu, Hsu-Shan Huang. Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.
Cells.
2021 08; 10(8):. doi:
10.3390/cells10081970. [PMID: 34440739] - Paul Dent, Laurence Booth, Andrew Poklepovic, Daniel Von Hoff, Jennifer Martinez, Yong Zhou, John F Hancock. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
Biochemical pharmacology.
2021 08; 190(?):114642. doi:
10.1016/j.bcp.2021.114642. [PMID: 34077739] - Xueting Cai, Jing Miao, Rongwei Sun, Sainan Wang, Miguel Angel Molina-Vila, Imane Chaib, Rafael Rosell, Peng Cao. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Pharmacological research.
2021 08; 170(?):105701. doi:
10.1016/j.phrs.2021.105701. [PMID: 34087353] - O S H Chan, V H F Lee, S F Nyaw, M T Y Kam, K W C Lee, K C Lam. Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme.
Clinical oncology (Royal College of Radiologists (Great Britain)).
2021 07; 33(7):e305-e314. doi:
10.1016/j.clon.2021.01.011. [PMID: 33589348] - Naoko Sueoka-Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Cancer medicine.
2021 06; 10(12):3873-3885. doi:
10.1002/cam4.3929. [PMID: 33982444] - Ryo Ariyasu, Ken Uchibori, Takaaki Sasaki, Mika Tsukahara, Kazuma Kiyotani, Ryohei Yoshida, Yusuke Ono, Satoru Kitazono, Hironori Ninomiya, Yuichi Ishikawa, Yusuke Mizukami, Noriko Yanagitani, Naoya Fujita, Makoto Nishio, Ryohei Katayama. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Cancer science.
2021 Jun; 112(6):2371-2380. doi:
10.1111/cas.14879. [PMID: 33686722] - Rie Furukawa, Hiroyuki Inoue, Yasuto Yoneshima, Hirono Tsutsumi, Eiji Iwama, Yuki Ikematsu, Nobuhisa Ando, Yoshimasa Shiraishi, Keiichi Ota, Kentaro Tanaka, Yoichi Nakanishi, Isamu Okamoto. Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands).
2021 05; 155(?):144-150. doi:
10.1016/j.lungcan.2021.03.018. [PMID: 33819860] - Mariano Provencio, Roberto Serna-Blasco, Fabio Franco, Virgina Calvo, Ana Royuela, Milda Auglytė, Alfredo Sánchez-Hernández, María de Julián Campayo, Carlos García-Girón, Manuel Dómine, Ana Blasco, José M Sánchez, Juana Oramas, Joaquim Bosch-Barrera, María Á Sala, María Sereno, Ana L Ortega, Luis Chara, Berta Hernández, Airam Padilla, Juan Coves, Remedios Blanco, José Balsalobre, Xabier Mielgo, Coralia Bueno, Eloisa Jantus-Lewintre, Miguel Á Molina-Vila, Atocha Romero. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
European journal of cancer (Oxford, England : 1990).
2021 05; 149(?):61-72. doi:
10.1016/j.ejca.2021.02.031. [PMID: 33831609] - Akihiro Tamiya, Shun-Ichi Isa, Yoshihiko Taniguchi, Hideyuki Nakagawa, Shinji Atagi, Masahiko Ando, Yasuhiro Koh. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
Clinical lung cancer.
2021 05; 22(3):e336-e341. doi:
10.1016/j.cllc.2020.05.023. [PMID: 32641247] - Chihiro Mimura, Masatsugu Yamamoto, Mana Nameta, Miyu Fujioka, Kiyoko Koyama, Masako Yumura, Tomomi Terashita, Naoko Katsurada, Kanoko Umezawa, Motoko Tachihara, Kazuyuki Kobayashi, Yoshihiro Nishimura. [A Case of Multiple Brain Tumors Successfully Diagnosed with Liquid Biopsy and Treated with Osimertinib].
Gan to kagaku ryoho. Cancer & chemotherapy.
2021 May; 48(5):677-679. doi:
NULL. [PMID: 34006712] - Anna Buder, Ellen Heitzer, Julie Waldispühl-Geigl, Sabrina Weber, Tina Moser, Maximilian J Hochmair, Klaus Hackner, Peter Errhalt, Ulrike Setinek, Martin Filipits. Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
Biomolecules.
2021 04; 11(5):. doi:
10.3390/biom11050618. [PMID: 33919291] - Wang Chun Kwok, James Chung Man Ho, David Chi Leung Lam, Macy Mei Sze Lui, Mary Sau Man Ip, Terence Chi Chun Tam. When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival.
Asia-Pacific journal of clinical oncology.
2021 Apr; 17(2):e35-e39. doi:
10.1111/ajco.13287. [PMID: 31802642] - Tereza Vaclova, Ursula Grazini, Lewis Ward, Daniel O'Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan Hartmaier, Kenneth S Thress, Paul D Smith, J Carl Barrett, Julian Downward, Elza C de Bruin. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Nature communications.
2021 03; 12(1):1780. doi:
10.1038/s41467-021-22057-8. [PMID: 33741979] - Xiufeng Cong, Jun Chen, Wei Zheng. The combination of camrelizumab and apatinib obtained ongoing partial remission for a patient with osimertinib-resistant non-small cell lung cancer: case report.
Annals of palliative medicine.
2021 Mar; 10(3):3469-3474. doi:
10.21037/apm-19-462. [PMID: 33040541] - Jared C Nesvet, Katie A Antilla, Danielle S Pancirer, Alexander X Lozano, Jordan S Preiss, Weijie Ma, Aihua Fu, Seung-Min Park, Sanjiv S Gambhir, Alice C Fan, Joel W Neal, Sukhmani K Padda, Millie Das, Tianhong Li, Heather A Wakelee, Shan X Wang. Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
Clinical chemistry.
2021 03; 67(3):534-542. doi:
10.1093/clinchem/hvaa307. [PMID: 33393992] - Tara Spence, Sheron Perera, Jessica Weiss, Sylvie Grenier, Laura Ranich, Frances Shepherd, Tracy L Stockley. Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer.
Journal of clinical pathology.
2021 Feb; 74(2):91-97. doi:
10.1136/jclinpath-2020-206668. [PMID: 32471890] - Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Ben-Yuan Jiang, Jin-Ji Yang, Qing Zhou, Chong-Rui Xu, Xiao-Rong Yang, Yi-Long Wu. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2021 02; 16(2):250-258. doi:
10.1016/j.jtho.2020.10.008. [PMID: 33122107] - Michael L Cheng, Christie J Lau, Marina S D Milan, Julianna G Supplee, Jonathan W Riess, Penelope A Bradbury, Pasi A Jänne, Geoffrey R Oxnard, Cloud P Paweletz. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.
JCO precision oncology.
2021; 5(?):. doi:
10.1200/po.20.00419. [PMID: 34250387] - Anna Buder, Maximilian J Hochmair, Martin Filipits. The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.
Targeted oncology.
2021 01; 16(1):77-84. doi:
10.1007/s11523-020-00781-3. [PMID: 33270169] - Keatdamrong Janpipatkul, Narumol Trachu, Piyakarn Watcharenwong, Wittaya Panvongsa, Wittawin Worakitchanon, Chanatip Metheetrairut, Songporn Oranratnachai, Thanyanan Reungwetwattana, Arthit Chairoungdua. Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.
Cancer biomarkers : section A of Disease markers.
2021; 31(3):281-294. doi:
10.3233/cbm-203075. [PMID: 33896827] - Nicola Colclough, Kan Chen, Peter Johnström, Nicole Strittmatter, Yumei Yan, Gail L Wrigley, Magnus Schou, Richard Goodwin, Katarina Varnäs, Sally J Adua, Minghui Zhao, Don X Nguyen, Gareth Maglennon, Peter Barton, James Atkinson, Lin Zhang, Annika Janefeldt, Joanne Wilson, Aaron Smith, Akihiro Takano, Ryosuke Arakawa, Mikhail Kondrashov, Jonas Malmquist, Evgeny Revunov, Ana Vazquez-Romero, Mohammad Mahdi Moein, Albert D Windhorst, Natasha A Karp, M Raymond V Finlay, Richard A Ward, James W T Yates, Paul D Smith, Lars Farde, Zack Cheng, Darren A E Cross. Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 01; 27(1):189-201. doi:
10.1158/1078-0432.ccr-19-1871. [PMID: 33028591] - Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, Koichi Azuma, Masayuki Takeda, Terufumi Kato, Haruko Daga, Isamu Okamoto, Hiroaki Akamatsu, Shunsuke Teraoka, Akira Ono, Tatsuo Ohira, Toshihide Yokoyama, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Kazuto Nishio. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Molecular oncology.
2021 01; 15(1):126-137. doi:
10.1002/1878-0261.12841. [PMID: 33131198] - Nagavendra Kommineni, Ebony Nottingham, Arvind Bagde, Nilkumar Patel, Arun K Rishi, Satyanarayan R S Dev, Mandip Singh. Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2021 Jan; 158(?):172-184. doi:
10.1016/j.ejpb.2020.11.007. [PMID: 33220423] - Ligang Xing, Yueyin Pan, Yuankai Shi, Yongqian Shu, Jifeng Feng, Wei Li, Lejie Cao, Lifeng Wang, Wei Gu, Yong Song, Puyuan Xing, Yutao Liu, Wen Gao, Jiuwei Cui, Nana Hu, Rutian Li, Hua Bao, Yang Shao, Jinming Yu. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 12; 26(23):6168-6175. doi:
10.1158/1078-0432.ccr-20-2081. [PMID: 32817079] - Su-Zhen Zhou, Han Li, Zhi-Wan Wang, Ming-Hang Wang, Ning Li, Yan-Fang Wang. LncRNA TSLNC8 synergizes with EGFR inhibitor osimertinib to inhibit lung cancer tumorigenesis by blocking the EGFR-STAT3 pathway.
Cell cycle (Georgetown, Tex.).
2020 11; 19(21):2776-2792. doi:
10.1080/15384101.2020.1820697. [PMID: 33064977] - Xiaoyun Lu, Jeff B Smaill, Ke Ding. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Journal of medicinal chemistry.
2020 10; 63(19):10726-10741. doi:
10.1021/acs.jmedchem.0c00507. [PMID: 32432477] - Zhen Xiao, Zhihui Zhou, Cilong Chu, Qian Zhang, Lingjia Zhou, Zunhua Yang, Xin Li, Liying Yu, Pengwu Zheng, Shan Xu, Wufu Zhu. Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations.
European journal of medicinal chemistry.
2020 Oct; 203(?):112511. doi:
10.1016/j.ejmech.2020.112511. [PMID: 32679450] - Xiaoyun Liu, Dan Feng, Mingyue Zheng, Yongmei Cui, Dafang Zhong. Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.
Drug metabolism and pharmacokinetics.
2020 Oct; 35(5):456-465. doi:
10.1016/j.dmpk.2020.07.002. [PMID: 32847720] - Dana Leng Hui Chan, Grace Li Xian Toh, Liuh Ling Goh. Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients.
Experimental and molecular pathology.
2020 10; 116(?):104515. doi:
10.1016/j.yexmp.2020.104515. [PMID: 32738312] - Qingjun Wu, Hui Jiang, Shuanghu Wang, Dapeng Dai, Feifei Chen, Deru Meng, Peiwu Geng, Hongfeng Tong, Yunfang Zhou, Debiao Pan, Quan Zhou, Chunjie Wang. Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats.
Thoracic cancer.
2020 10; 11(10):2775-2781. doi:
10.1111/1759-7714.13587. [PMID: 32812378] - Karthick Vishwanathan, Inmaculada Sanchez-Simon, Bhumsuk Keam, Nicolas Penel, Maria de Miguel-Luken, Doris Weilert, Andrew Mills, Marcelo Marotti, Martin Johnson, Alain Ravaud. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
Pharmacology research & perspectives.
2020 08; 8(4):e00613. doi:
10.1002/prp2.613. [PMID: 32567817] - Vincent Chen, Eiji Iwama, In-Kyu Kim, Giuseppe Giaccone. Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands).
2020 07; 145(?):48-57. doi:
10.1016/j.lungcan.2020.04.032. [PMID: 32408132] - Jamie J Beagan, Sander Bach, Robert A van Boerdonk, Erik van Dijk, Erik Thunnissen, Daan van den Broek, Janneke Weiss, Geert Kazemier, D Michiel Pegtel, Idris Bahce, Bauke Ylstra, Daniëlle A M Heideman. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
Lung cancer (Amsterdam, Netherlands).
2020 07; 145(?):173-180. doi:
10.1016/j.lungcan.2020.04.039. [PMID: 32460198] - Marco Russano, Fabrizio Citarella, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini. Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2020 07; 15(7):e105-e106. doi:
10.1016/j.jtho.2020.04.001. [PMID: 32283315] - Adam J Schoenfeld, Joseph M Chan, Daisuke Kubota, Hiroki Sato, Hira Rizvi, Yahya Daneshbod, Jason C Chang, Paul K Paik, Michael Offin, Maria E Arcila, Monika A Davare, Ujwal Shinde, Dana Pe'er, Natasha Rekhtman, Mark G Kris, Romel Somwar, Gregory J Riely, Marc Ladanyi, Helena A Yu. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 06; 26(11):2654-2663. doi:
10.1158/1078-0432.ccr-19-3563. [PMID: 31911548] - Qinfang Deng, Qiyu Fang, Boxiong Xie, Hui Sun, Yuchen Bao, Songwen Zhou. Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer.
Aging.
2020 05; 12(9):8001-8015. doi:
10.18632/aging.103119. [PMID: 32375124] - Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, Kenji Chibana, Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
BMC cancer.
2020 May; 20(1):370. doi:
10.1186/s12885-020-06874-6. [PMID: 32357848] - Hongyan Zhang, Conghua Xie, Yihua Huang. Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2020 05; 15(5):e63-e64. doi:
10.1016/j.jtho.2020.02.025. [PMID: 32147577] - Xin Zhang, Fang Xu, Linjiang Tong, Tao Zhang, Hua Xie, Xiaoyun Lu, Xiaomei Ren, Ke Ding. Design and synthesis of selective degraders of EGFRL858R/T790M mutant.
European journal of medicinal chemistry.
2020 Apr; 192(?):112199. doi:
10.1016/j.ejmech.2020.112199. [PMID: 32171162] - Ard van Veelen, Robin van Geel, Yvo de Beer, Anne-Marie Dingemans, Leo Stolk, Rob Ter Heine, Frank de Vries, Sander Croes. Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.
Biomedical chromatography : BMC.
2020 Apr; 34(4):e4771. doi:
10.1002/bmc.4771. [PMID: 31808583] - X H Kang, K Wang, Y Wang, H K Zhao, J Zhang, K L Zhao, Z H Miao, Z Y Xu, F Cao, Y B Gong. [Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells].
Zhonghua zhong liu za zhi [Chinese journal of oncology].
2020 Mar; 42(3):210-215. doi:
10.3760/cma.j.cn112152-20190322-00186. [PMID: 32252199] - Haoquan He, Zheng Liu, Wei Wang, Xiaojian Jiang. Synthesis and cytotoxic evaluation of halogenated α-exo-methylene-lactones.
Bioorganic & medicinal chemistry.
2020 02; 28(3):115281. doi:
10.1016/j.bmc.2019.115281. [PMID: 31889606] - Hidenobu Ishii, Koichi Azuma, Kazuko Sakai, Yoshiko Naito, Norikazu Matsuo, Takaaki Tokito, Kazuhiko Yamada, Tomoaki Hoshino, Kazuto Nishio. Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Scientific reports.
2020 01; 10(1):691. doi:
10.1038/s41598-020-57624-4. [PMID: 31959859] - Vassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, Suresh S Ramalingam, Angelo Delmonte, Te-Chun Hsia, Janessa Laskin, Sang-We Kim, Yong He, Chun-Ming Tsai, Toyoaki Hida, Makoto Maemondo, Terufumi Kato, Suzanne Jenkins, Sabina Patel, Xiangning Huang, Gianluca Laus, Aleksandra Markovets, Kenneth S Thress, Yi-Long Wu, Tony Mok. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Cancer.
2020 01; 126(2):373-380. doi:
10.1002/cncr.32503. [PMID: 31769875] - Takayuki Takahama, Koichi Azuma, Mototsugu Shimokawa, Masayuki Takeda, Hidenobu Ishii, Terufumi Kato, Haruhiro Saito, Haruko Daga, Yuko Tsuboguchi, Isamu Okamoto, Kohei Otsubo, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takahashi, Akira Ono, Tatsuo Ohira, Toshihide Yokoyama, Kazuko Sakai, Nobuyuki Yamamoto, Kazuto Nishio, Kazuhiko Nakagawa. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Cancer.
2020 01; 126(9):1940-1948. doi:
10.1002/cncr.32749. [PMID: 32022929] - Karthick Vishwanathan, Mireille Cantarini, Karen So, Eric Masson, Jennifer Fetterolf, Suresh S Ramalingam, R Donald Harvey. Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.
Clinical and translational science.
2020 01; 13(1):41-46. doi:
10.1111/cts.12688. [PMID: 31498564] - Chia-Chi Hsu, Bin-Chi Liao, Wei-Yu Liao, Aleksandra Markovets, Daniel Stetson, Kenneth Thress, James Chih-Hsin Yang. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2020 01; 15(1):50-61. doi:
10.1016/j.jtho.2019.09.006. [PMID: 31557536] - Nuo Yang, Ruirong Wan, Lei Dai, Yongyong Wang, Xiang Tan, Mingwu Chen, Jianji Guo, Huafu Zhou. Effect of Osimertinib on the expression of serum mmp-7 and mmp-9 in patients with non-small cell lung cancer.
Pakistan journal of pharmaceutical sciences.
2020 Jan; 33(1(Special)):499-504. doi:
NULL. [PMID: 32173649] - Bingbing Zhao, Chengwu Zhao, Xiaohan Hu, Shan Xu, Zhou Lan, Yuping Guo, Zunhua Yang, Wufu Zhu, Pengwu Zheng. Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells.
European journal of medicinal chemistry.
2020 Jan; 185(?):111809. doi:
10.1016/j.ejmech.2019.111809. [PMID: 31683104] - Xiaoqi Wang, Wenxing Mao, Zhi Wang, Xinrui Li, Yaokun Xiong, Hongjin Lu, Xiuzhen Wang, Haoyuan Yin, Xiang Cao, Hongliang Xin. Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier.
International journal of nanomedicine.
2020; 15(?):5491-5501. doi:
10.2147/ijn.s258699. [PMID: 32848385] - Kaja Karaś, Anna Sałkowska, Iwona Karwaciak, Aurelia Walczak-Drzewiecka, Jarosław Dastych, Rafał A Bachorz, Marcin Ratajewski. The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT.
International journal of molecular sciences.
2019 Nov; 20(22):. doi:
10.3390/ijms20225780. [PMID: 31744223] - Jhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, Johan Vansteenkiste, Fumio Imamura, Jong Seok Lee, Yong-Kek Pang, Manuel Cobo, Kazuo Kasahara, Ying Cheng, Naoyuki Nogami, Eun Kyung Cho, Wu Chou Su, Guili Zhang, Xiangning Huang, Xiaocheng Li-Sucholeiki, Brian Lentrichia, Simon Dearden, Suzanne Jenkins, Matilde Saggese, Yuri Rukazenkov, Suresh S Ramalingam. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019 11; 25(22):6644-6652. doi:
10.1158/1078-0432.ccr-19-1126. [PMID: 31439584] - Sebastian Mondaca, Michael Offin, Laetitia Borsu, Mackenzie Myers, Sowmya Josyula, Alex Makhnin, Ronglai Shen, Gregory J Riely, Charles M Rudin, Marc Ladanyi, Helena A Yu, Bob T Li, Maria E Arcila. Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.
Acta oncologica (Stockholm, Sweden).
2019 Nov; 58(11):1634-1639. doi:
10.1080/0284186x.2019.1645354. [PMID: 31347936] - Camille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, Roger Lacave, Anaïs Pujals, Nicolas Girard, Céline Callens, Valérie Gounant, Nathalie Théou-Anton, Sylvie Friard, Jean Trédaniel, Hélène Blons, Cécile Dujon, Boris Duchemann, Pierre Olivier Schischmanoff, Thierry Chinet, Etienne Giroux Leprieur. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Lung cancer (Amsterdam, Netherlands).
2019 11; 137(?):149-156. doi:
10.1016/j.lungcan.2019.09.019. [PMID: 31600593] - Pei N Ding, Therese Becker, Victoria Bray, Wei Chua, Yafeng Ma, Bo Xu, David Lynch, Paul de Souza, Tara Roberts. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.
Thoracic cancer.
2019 10; 10(10):1879-1884. doi:
10.1111/1759-7714.13154. [PMID: 31414729] - Po-Lan Su, Szu-Chun Yang, Yi-Lin Chen, Yi-Lin Wu, Chia-Ying Lin, Wei-Yuan Chang, Yau-Lin Tseng, Wu-Wei Lai, Chung-Liang Ho, Chien-Chung Lin, Wu-Chou Su. Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment.
Cancer medicine.
2019 10; 8(13):5939-5947. doi:
10.1002/cam4.2485. [PMID: 31433117] - J Gao, H-R Li, C Jin, J-H Jiang, J-Y Ding. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2019 Oct; 21(10):1287-1301. doi:
10.1007/s12094-019-02075-1. [PMID: 30864018] - Alessandro Leonetti, Sugandhi Sharma, Roberta Minari, Paola Perego, Elisa Giovannetti, Marcello Tiseo. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
British journal of cancer.
2019 10; 121(9):725-737. doi:
10.1038/s41416-019-0573-8. [PMID: 31564718] - Fei Cao, Ya-Bin Gong, Xiao-Hong Kang, Zhi-Hong Lu, Ying Wang, Ke-Lei Zhao, Zhan-Hui Miao, Ming-Juan Liao, Zhen-Ye Xu. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.
Toxicology and applied pharmacology.
2019 09; 379(?):114662. doi:
10.1016/j.taap.2019.114662. [PMID: 31301315] - Julie M Janssen, Niels de Vries, Nikkie Venekamp, Hilde Rosing, Alwin D R Huitema, Jos H Beijnen. Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma.
Journal of pharmaceutical and biomedical analysis.
2019 Sep; 174(?):561-566. doi:
10.1016/j.jpba.2019.06.034. [PMID: 31255856] - Emiliano Calvo, Jong-Seok Lee, Sang-We Kim, Victor Moreno, Javier deCastro Carpeno, Doris Weilert, Gianluca Laus, Helen Mann, Karthick Vishwanathan. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Journal of clinical pharmacology.
2019 08; 59(8):1099-1109. doi:
10.1002/jcph.1403. [PMID: 30875094] - Stéphanie van Hoppe, Amer Jamalpoor, Johannes J M Rood, Els Wagenaar, Rolf W Sparidans, Jos H Beijnen, Alfred H Schinkel. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
Pharmacological research.
2019 08; 146(?):104297. doi:
10.1016/j.phrs.2019.104297. [PMID: 31175939]